Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emerging Markets Earnings Roundup: Abbott, AbbVie, J&J And Novartis (Part 3)

This article was originally published in PharmAsia News

Executive Summary

In Part 3 of our feature, we take a closer look at the first quarterly calls for Abbott and AbbVie after the company split in two, plus the latest on emerging markets from J&J and Novartis.

You may also be interested in...



AbbVie Sets Out To Win Over Investors In Its First Financial Call

Management highlighted the ongoing growth potential of Humira and a late-stage pipeline that it says has the ability to generate between $4 billion and $6 billion of growth during the new pharmaceutical company’s first financial call with investors.

J&J Considers Sale, Spin-Off For Ortho-Clinical Diagnostics

Johnson & Johnson announced plans to evaluate strategic options for its Ortho-Clinical Diagnostics unit during the firm’s medical devices and diagnostics business review.

Top Changes At Bayer And Novartis As Vasella Goes, Reinhardt Returns

It’s all change at two of Europe’s largest pharmaceutical concerns as leading light Daniel Vasella retires at Novartis and Bayer Healthcare’s chairman Jorg Reinhardt moves across to replace him as non-executive chairman.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC083617

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel